| 09/27/2024 11:30 |
Shionogi Submits New Drug Application in Japan for Zuranolone as a Treatment for Major Depressive Disorder |
| 08/30/2024 14:00 |
Notice Regarding Stock Split, Partial Amendment to Articles of Incorporation and Revision of Dividend Forecast |
| 08/05/2024 15:00 |
New Drug Application of Novel Siderophore Cephalosporin Antibiotics, Cefiderocol, Accepted in China |
| 07/29/2024 15:00 |
Consolidated Financial Results for the First Quarter of Fiscal Year 2024 (IFRS) |
| 07/29/2024 15:00 |
Supplemental material for financial results for the 1st quarter of fiscal year 2024 |
| 07/29/2024 15:00 |
1st Quarter of Fiscal 2024 Financial Results |
| 07/19/2024 15:00 |
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 07/01/2024 13:00 |
Corporate Governance Report |
| 06/24/2024 16:00 |
COVGOZE (Monovalent: Original Strain), Recombinant Protein COVID-19 Vaccine, Approved for Manufacturing and Marketing as Initial Immunization in Japan |
| 06/20/2024 17:00 |
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 06/06/2024 17:00 |
SHIONOGI R&D Day 2024 |
| 06/06/2024 17:00 |
SHIONOGI R&D Day 2024 |
| 05/31/2024 15:00 |
Position and Policy Regarding Reduction of the Investment Unit |
| 05/22/2024 08:00 |
Notice of Convocation of Annual General Meeting and Meeting Materials 2024 |
| 05/13/2024 15:00 |
Shionogi Provides Updates from SCORPIO-HR, a Global Phase 3 Study of Ensitrelvir for Non-Hospitalized Participants with COVID-19 |
| 05/13/2024 15:00 |
FY2023 Finacial Results |
| 05/13/2024 13:00 |
Financial results for the year ended March 31, 2024 |
| 05/13/2024 13:00 |
Consolidaterd Financial Resauts for Fiscal Year 2023 (IFRS) |
| 05/10/2024 15:00 |
Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease |
| 04/25/2024 15:00 |
Notice of Revisions to Dividend Forecasts (Dividend Increase) |
| 04/23/2024 17:00 |
Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents |
| 04/18/2024 11:30 |
Notice Regarding Completion of Cancellation of Treasury Shares |
| 03/28/2024 16:00 |
Notice Regarding the Status and Completion of Acquisition of Own Shares |
| 03/05/2024 15:00 |
Shionogi Announces Xocova (Ensitrelvir Fumaric Acid) Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection |
| 03/05/2024 15:00 |
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares |
| 02/06/2024 16:00 |
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares |
| 01/31/2024 13:00 |
3rd Quarter of Fiscal 2023 Financial Results |
| 01/31/2024 13:00 |
Supplemental material for financial results for the 3rd quarter of fiscal year 2023 |
| 01/31/2024 13:00 |
Consolidated Financial Results for the Third Quarter of Fiscal Year 2023 (IFRS) |
| 01/10/2024 15:00 |
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares |
| 12/20/2023 11:30 |
New Siderophore Cephalosporin Antibiotic Fetroja Launches in Japan, Along with the Release of Reagents for Antimicrobial Susceptibility Testing |
| 12/18/2023 11:30 |
Initiation of a Phase 3 Additional Dose Clinical Trial in Japanese Subjects of the Monovalent Vaccine for the XBB1.5 Strain, S-268023 |
| 12/07/2023 15:00 |
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares |
| 11/30/2023 15:00 |
Regarding the Acquisition of Manufacturing and Marketing Approval for the New Siderophore Cephalosporin Antibiotic Fetroja(cefiderocol) |
| 11/08/2023 16:00 |
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares |
| 10/31/2023 13:00 |
1st Half of Fiscal 2023 Financial Results |
| 10/31/2023 13:00 |
Financial Results for the Second Quarter of Fiscal Year 2023 |
| 10/31/2023 13:00 |
Consolidated Finacial Results for the Second Quarter of Fiscal Year 2023 (IFRS) |
